Ubrogepant, popularly sold under the brand name Ubrelvy, is a pivotal medication utilized primarily for the acute treatment of migraines with or without aura in adults. However, it's important to note that it's not indicated for the preventive treatment of migraines. An integral part of the CGRP receptor antagonist family, Ubrogepant is a highly potent, small-molecule calcitonin gene-related peptide (CGRP) antagonist. It functions by blocking the CGRP ligands from binding to the CGRP receptor. This sophisticated mechanism enables Ubrogepant to effectively alleviate the painful symptoms of a migraine attack.
![3- ((6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)carbamoyl)- 2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[ 2,3-b]pyridine] 7′ oxide](https://veeprho.com/wp-content/uploads/2024/07/Ubrogepant-Impurity-6.png "3- ((6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)carbamoyl)- 2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[ 2,3-b]pyridine] 7′ oxide")
Parent: Ubrogepant
![3-((6-methyl-2-oxo-5-phenyl- 1-(2,2,2-trifluoroethyl)piperidin-3 yl)carbamoyl)-2′-oxo-1′,2′,5,7 tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine] 1-oxide](https://veeprho.com/wp-content/uploads/2024/07/Ubrogepant-Impurity-7.png "3-((6-methyl-2-oxo-5-phenyl- 1-(2,2,2-trifluoroethyl)piperidin-3 yl)carbamoyl)-2′-oxo-1′,2′,5,7 tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine] 1-oxide")
Parent: Ubrogepant
Like all pharmaceuticals, Ubrogepant may contain a safe level of impurities and related compounds. Impurities arise due to various factors including the manufacturing process, degradation over time, etc. It’s essential to know that the presence of impurities does not necessarily compromise the effectiveness of Ubrogepant, as the amount is typically infinitesimal. The detection, identification, quantification, and validation of impurities in the drug is part of routine quality control in pharmaceutical manufacturing. All impurities are strictly regulated and evaluated to ensure the safety and efficacy of the drug.
Ubrogepant tablets are used for the acute treatment of migraine with or without aura in adults. It helps alleviate the symptoms of migraines. However, it should be noted that Ubrogepant is not a preventive treatment for migraines.
Ubrogepant is a relatively new drug and its novel mechanism of action is more complex compared to other migraine treatments. The pricing of Ubrogepant also factors in the cost of drug research, development, and obtaining FDA approval.
Ubrogepant is a highly potent, small molecule calcitonin gene-related peptide (CGRP) antagonist. It works by blocking the CGRP ligands from binding to the CGRP receptor. By doing so, it helps alleviate the painful symptoms of acute migraine attacks.
The availability of Ubrogepant in India may vary. It’s advisable to check with local pharmacies or consult with healthcare professionals about its availability and equivalent options.
